SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 46.60 |
| Enterprise Value ($M) | -14.66 |
| Book Value ($M) | 20.97 |
| Book Value / Share | 0.48 |
| Price / Book | 2.22 |
| NCAV ($M) | 7.58 |
| NCAV / Share | 0.17 |
| Price / NCAV | 6.15 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -2.14 |
| Return on Assets (ROA) | -1.03 |
| Return on Equity (ROE) | -1.71 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.78 |
| Current Ratio | 1.78 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 61.26 |
| Assets | 74.66 |
| Liabilities | 53.68 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Abbvie Inc. | |||
| 13G/A | Gilead Sciences Inc | |||
| 13G/A | Bain Capital Life Sciences Fund II, L.P. | 9.99 | 238.61 | |
| 13G/A | Atlas Venture Fund XI, L.P. | 0.00 | -100.00 | |
| 13G/A | Fmr Llc | 3.17 | -26.83 | |
| 13G/A | Rock Springs Capital Management LP | 6.83 | 0.00 | |
| 13G | Gkcc, Llc | 15.90 | ||
| 13G/A | Takeda Pharmaceutical Co Ltd | 4.00 | 0.00 | |
| 13G/A | Octagon Capital Advisors LP | 0.00 | -100.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 821,206 | 2,801,640 | 29.31 | |
| 928,429 | 3,190,712 | 29.10 | |
| 1,056,543 | 3,515,225 | 30.06 | |
| 1,016,286 | 3,218,292 | 31.58 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| VYGR – Voyager Therapeutics, Inc. | XBIT – XBiotech Inc. |
| XERS – Xeris Biopharma Holdings, Inc. | YMAB – Y-mAbs Therapeutics, Inc. |
| ZVRA – Zevra Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io